During the recent session, Seres Therapeutics Inc (NASDAQ:MCRB)’s traded shares were 1.13 million, with the beta value of the company hitting 2.09. At the last check today, the stock’s price was $0.89, reflecting an intraday gain of 3.67% or $0.03. The 52-week high for the MCRB share is $2.05, that puts it down -130.34 from that peak though still a striking 39.33% gain since the share price plummeted to a 52-week low of $0.54. The company’s market capitalization is $152.32M, and the average intraday trading volume over the past 10 days was 3.2 million shares, and the average trade volume was 3.70 million shares over the past three months.
Seres Therapeutics Inc (MCRB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.25. MCRB has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Seres Therapeutics Inc (MCRB) registered a 3.67% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.67% in intraday trading to $0.89, hitting a weekly high. The stock’s 5-day price performance is 8.36%, and it has moved by 51.15% in 30 days. Based on these gigs, the overall price performance for the year is -15.04%. The short interest in Seres Therapeutics Inc (NASDAQ:MCRB) is 17.38 million shares and it means that shorts have 5.18 day(s) to cover.
The consensus price target of analysts on Wall Street is $1.25, which implies an increase of 28.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.25 and $1.25 respectively. As a result, MCRB is trading at a discount of -40.45% off the target high and -40.45% off the low.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Statistics show that Seres Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Seres Therapeutics Inc (MCRB) shares have gone up 25.95% during the last six months, with a year-to-date growth rate more than the industry average at 57.30% against 17.10. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 12.5M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.22%. While earnings are projected to return 86.61% in 2024.
MCRB Dividends
Seres Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Seres Therapeutics Inc insiders own 13.19% of total outstanding shares while institutional holders control 37.18%, with the float percentage being 42.83%. FLAGSHIP PIONEERING INC. is the largest shareholder of the company, while 90.0 institutions own stock in it. As of 2024-06-30, the company held over 23.12 million shares (or 15.8226% of all shares), a total value of $16.73 million in shares.
The next largest institutional holding, with 22.72 million shares, is of FMR LLC’s that is approximately 15.5489% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $16.44 million.
